Aktienanalyse zu Repligen Corp (RGEN)RGENRepligen Corp

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Repligen Corp is a good buy right now due to its strong revenue growth, with Q2 2026 revenue reported at $204.13 million, up 25.01% over the last 20 days. Additionally, the company has a solid gross margin of 53.91%, which supports profitability. The main risk is its high forward P/E ratio of 87.72, indicating that the stock may be overvalued if growth does not meet expectations.

6 analysts cover RGEN: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 189.00.